Clinical Trials
8 trialsNCT06585488 2026-06-03
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
BeOne Medicines
Phase 1 Terminated
NCT06487858 2026-05-11
A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors
BeOne Medicines
Phase 1 Terminated
NCT06540066 2026-03-16
A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
BeOne Medicines
Phase 1 Terminated
NCT05935098 2026-03-13
BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors
BeOne Medicines
Phase 1 Terminated
NCT04294160 2025-12-24
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
Novartis
Phase 1 Terminated
NCT05904496 2025-09-16
A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
BeiGene
Phase 1 Terminated
NCT04261439 2025-05-06
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab
Novartis
Phase 1 Terminated
NCT05494762 2025-05-01
Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors
BeiGene
Phase 1 Terminated